Skip to main content
Top
Published in: Supportive Care in Cancer 7/2020

01-07-2020 | Care | Original Article

Estimating survival in advanced cancer: a comparison of estimates made by oncologists and patients

Authors: M. E. S. Smith-Uffen, S. B. Johnson, A. J. Martin, M. H. N. Tattersall, M. R. Stockler, M. L. Bell, K. Detering, J. M. Clayton, W. Silvester, S. Clarke, L. Vaccaro, P. Beale, B. E. Kiely

Published in: Supportive Care in Cancer | Issue 7/2020

Login to get access

Abstract

Purpose

To compare estimates of expected survival time (EST) made by patients with advanced cancer and their oncologists.

Methods

At enrolment patients recorded their “understanding of how long you may have to live” in best-case, most-likely, and worst-case scenarios. Oncologists estimated survival time for each of their patients as the “median survival of a group of identical patients”. We hypothesized that oncologists’ estimates of EST would be unbiased (~ 50% longer or shorter than the observed survival time [OST]), imprecise (< 33% within 0.67 to 1.33 times OST), associated with OST, and more accurate than patients’ estimates of their own survival.

Results

Twenty-six oncologists estimated EST for 179 patients. The median estimate of EST was 6.0 months, and the median OST was 6.2 months. Oncologists’ estimates were unbiased (56% longer than OST), imprecise (27% within 0.67 to 1.33 times OST), and significantly associated with OST (HR 0.88, 95% CI 0.82 to 0.93, p < 0.01). Only 41 patients (23%) provided a numerical estimate of their survival with 107 patients (60%) responding “I don’t know”. The median estimate by patients for their most-likely scenario was 12 months. Patient estimates of their most-likely scenario were less precise (17% within 0.67 to 1.33 times OST) and more likely to overestimate survival (85% longer than OST) than oncologist estimates.

Conclusion

Oncologists’ estimates were unbiased and significantly associated with survival. Most patients with advanced cancer did not know their EST or overestimated their survival time compared to their oncologist, highlighting the need for improved prognosis communication training.
Trial registration ACTRN1261300128871
Literature
1.
go back to reference Innes S, Payne S (2009) Advanced cancer patients' prognostic information preferences: a review. Palliat Med 23(1):29–39CrossRef Innes S, Payne S (2009) Advanced cancer patients' prognostic information preferences: a review. Palliat Med 23(1):29–39CrossRef
2.
go back to reference Hagerty R, Butow PN, Ellis PA, Lobb EA, Pendlebury S, Leighl N, Goldstein D, Lo SK, Tattersall MH (2004) Cancer patient preferences for communication of prognosis in the metastatic setting. J Clin Oncol 22:1721–1730CrossRef Hagerty R, Butow PN, Ellis PA, Lobb EA, Pendlebury S, Leighl N, Goldstein D, Lo SK, Tattersall MH (2004) Cancer patient preferences for communication of prognosis in the metastatic setting. J Clin Oncol 22:1721–1730CrossRef
3.
go back to reference Clayton J et al (2005) Discussing end-of-life issues with terminally ill cancer patients and their carers: a qualitative study. Support Care Cancer 13:589–599CrossRef Clayton J et al (2005) Discussing end-of-life issues with terminally ill cancer patients and their carers: a qualitative study. Support Care Cancer 13:589–599CrossRef
4.
go back to reference Weeks J, Cook EF, O'Day SJ, Peterson LM, Wenger N, Reding D, Harrell FE, Kussin P, Dawson NV, Connors AF Jr, Lynn J, Phillips RS (1998) Relationship between cancer patients’ predictions of prognosis and their treatment preferences. JAMA 279(21):1709–1714CrossRef Weeks J, Cook EF, O'Day SJ, Peterson LM, Wenger N, Reding D, Harrell FE, Kussin P, Dawson NV, Connors AF Jr, Lynn J, Phillips RS (1998) Relationship between cancer patients’ predictions of prognosis and their treatment preferences. JAMA 279(21):1709–1714CrossRef
5.
go back to reference Enzinger A, Zhang B, Schrag D, Prigerson HG (2015) Outcomes of prognostic disclosure: associations with prognostic understanding, distress, and relationship with physician among patients with advanced cancer. J Clin Oncol 33(32):3809–3816CrossRef Enzinger A, Zhang B, Schrag D, Prigerson HG (2015) Outcomes of prognostic disclosure: associations with prognostic understanding, distress, and relationship with physician among patients with advanced cancer. J Clin Oncol 33(32):3809–3816CrossRef
6.
go back to reference Prigerson H (1992) Socialization to dying: social determinants of death acknowledgment and treatment among terminally ill geriatric patients. J Health Soc Behav 33(4):378–395CrossRef Prigerson H (1992) Socialization to dying: social determinants of death acknowledgment and treatment among terminally ill geriatric patients. J Health Soc Behav 33(4):378–395CrossRef
7.
go back to reference Heyland D et al Discussing prognosis with patients and their families near the end of life: impact on satisfaction with end-of-life care. Open Med 3(2):e101–e110 Heyland D et al Discussing prognosis with patients and their families near the end of life: impact on satisfaction with end-of-life care. Open Med 3(2):e101–e110
8.
go back to reference Wright A, Zhang B, Ray A, Mack JW, Trice E, Balboni T, Mitchell SL, Jackson VA, Block SD, Maciejewski PK, Prigerson HG (2008) Associations between end-of-life discussions, patient mental health, medical care near death, and caregiver bereavement adjustment. J Am Med Assoc 300(14):1665–1673CrossRef Wright A, Zhang B, Ray A, Mack JW, Trice E, Balboni T, Mitchell SL, Jackson VA, Block SD, Maciejewski PK, Prigerson HG (2008) Associations between end-of-life discussions, patient mental health, medical care near death, and caregiver bereavement adjustment. J Am Med Assoc 300(14):1665–1673CrossRef
9.
go back to reference Eidinger R, Schapira D (1984) Cancer patients’ insight into their treatment, prognosis, and unconventional therapies. Cancer 53:2736–2740CrossRef Eidinger R, Schapira D (1984) Cancer patients’ insight into their treatment, prognosis, and unconventional therapies. Cancer 53:2736–2740CrossRef
10.
go back to reference Kiely B et al (2010) How long have I got? Estimating survival for women starting first-line chemotherapy for metastatic breast cancer (MBC): a systematic review of recent randomized trials. J Clin Oncol 28(15_suppl):9106–9106CrossRef Kiely B et al (2010) How long have I got? Estimating survival for women starting first-line chemotherapy for metastatic breast cancer (MBC): a systematic review of recent randomized trials. J Clin Oncol 28(15_suppl):9106–9106CrossRef
11.
go back to reference Epstein A, Prigerson HG, O'Reilly EM, Maciejewski PK (2016) Discussions of life expectancy and changes in illness understanding in patients with advanced cancer. J Clin Oncol 34:2398–2403CrossRef Epstein A, Prigerson HG, O'Reilly EM, Maciejewski PK (2016) Discussions of life expectancy and changes in illness understanding in patients with advanced cancer. J Clin Oncol 34:2398–2403CrossRef
12.
go back to reference Fenton J et al (2017) Impact of prognostic discussions on the patient-physician relationship: prospective cohort study. J Clin Oncol 36(3):225–231CrossRef Fenton J et al (2017) Impact of prognostic discussions on the patient-physician relationship: prospective cohort study. J Clin Oncol 36(3):225–231CrossRef
13.
go back to reference Anderson W, Chase R, Pantilat SZ, Tulsky JA, Auerbach AD (2011) Code status discussions between attending hospitalist physicians and medical patients at hospital admission. J Gen Intern Med 26:359–366CrossRef Anderson W, Chase R, Pantilat SZ, Tulsky JA, Auerbach AD (2011) Code status discussions between attending hospitalist physicians and medical patients at hospital admission. J Gen Intern Med 26:359–366CrossRef
14.
go back to reference The A, Hak T, Koëter G, van der Wal G (2000) Collusion in doctor-patient communication about imminent death: an ethnographic study. BMJ 321:1376–1381CrossRef The A, Hak T, Koëter G, van der Wal G (2000) Collusion in doctor-patient communication about imminent death: an ethnographic study. BMJ 321:1376–1381CrossRef
15.
go back to reference Kiely B, McCaughan G, Christodoulou S, Beale PJ, Grimison P, Trotman J, Tattersall MH, Stockler MR (2013) Using scenarios to explain life expectancy in advanced cancer: attitudes of people with a cancer experience. Support Care Cancer 21:369–376CrossRef Kiely B, McCaughan G, Christodoulou S, Beale PJ, Grimison P, Trotman J, Tattersall MH, Stockler MR (2013) Using scenarios to explain life expectancy in advanced cancer: attitudes of people with a cancer experience. Support Care Cancer 21:369–376CrossRef
16.
go back to reference Stockler M, Tattersall MH, Boyer MJ, Clarke SJ, Beale PJ, Simes RJ (2006) Disarming the guarded prognosis: predicting survival in newly referred patients with incurable cancer. Br J Cancer 94:208–212CrossRef Stockler M, Tattersall MH, Boyer MJ, Clarke SJ, Beale PJ, Simes RJ (2006) Disarming the guarded prognosis: predicting survival in newly referred patients with incurable cancer. Br J Cancer 94:208–212CrossRef
17.
go back to reference Kiely B, Martin AJ, Tattersall MH, Nowak AK, Goldstein D, Wilcken NR, Wyld DK, Abdi EA, Glasgow A, Beale PJ, Jefford M, Glare PA, Stockler MR (2013) The median informs the message: accuracy of individualized scenarios for survival time based on oncologists’ estimates. J Clin Oncol 31(28):3565–3571CrossRef Kiely B, Martin AJ, Tattersall MH, Nowak AK, Goldstein D, Wilcken NR, Wyld DK, Abdi EA, Glasgow A, Beale PJ, Jefford M, Glare PA, Stockler MR (2013) The median informs the message: accuracy of individualized scenarios for survival time based on oncologists’ estimates. J Clin Oncol 31(28):3565–3571CrossRef
19.
go back to reference Johnson SB, Butow PN, Bell ML, Detering K, Clayton JM, Silvester W, Kiely BE, Clarke S, Vaccaro L, Stockler MR, Beale P, Fitzgerald N, Tattersall MHN (2018) A randomised controlled trial of an advance care planning intervention for patients with incurable cancer. Br J Cancer 119(10):1182–1190CrossRef Johnson SB, Butow PN, Bell ML, Detering K, Clayton JM, Silvester W, Kiely BE, Clarke S, Vaccaro L, Stockler MR, Beale P, Fitzgerald N, Tattersall MHN (2018) A randomised controlled trial of an advance care planning intervention for patients with incurable cancer. Br J Cancer 119(10):1182–1190CrossRef
20.
go back to reference Christakis N, Lamont E (2000) Extent and determinants of error in doctors’ prognoses in terminally ill patients: prospective cohort study. BMJ 320:469–472CrossRef Christakis N, Lamont E (2000) Extent and determinants of error in doctors’ prognoses in terminally ill patients: prospective cohort study. BMJ 320:469–472CrossRef
21.
go back to reference Llobera J, Esteva M, Rifà J, Benito E, Terrasa J, Rojas C, Pons O, Catalán G, Avellà A (2000) Terminal cancer: duration and prediction of survival time. Eur J Cancer 36:2036–2043CrossRef Llobera J, Esteva M, Rifà J, Benito E, Terrasa J, Rojas C, Pons O, Catalán G, Avellà A (2000) Terminal cancer: duration and prediction of survival time. Eur J Cancer 36:2036–2043CrossRef
22.
go back to reference Faris M (2003) Clinical estimation of survival and impact of other prognostic factors on terminally ill cancer patients in Oman. Support Care Cancer 11:30–34CrossRef Faris M (2003) Clinical estimation of survival and impact of other prognostic factors on terminally ill cancer patients in Oman. Support Care Cancer 11:30–34CrossRef
23.
go back to reference Heyse-Moore L, Johnson-Bell V (1987) Can doctors accurately predict the life expectancy of patients with terminal cancer? Palliat Med 1:165–166CrossRef Heyse-Moore L, Johnson-Bell V (1987) Can doctors accurately predict the life expectancy of patients with terminal cancer? Palliat Med 1:165–166CrossRef
24.
go back to reference Harrell FJ, Lee K, Mark D (1996) Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med 15:361–387CrossRef Harrell FJ, Lee K, Mark D (1996) Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med 15:361–387CrossRef
25.
go back to reference Perez-Cruz P, Dos Santos R, Silva TB, Crovador CS, Nascimento MS, Hall S, Fajardo J, Bruera E, Hui D (2014) Longitudinal temporal and probabilistic prediction of survival in a cohort of patients with advanced cancer. J Pain Symptom Manag 48(5):875–882CrossRef Perez-Cruz P, Dos Santos R, Silva TB, Crovador CS, Nascimento MS, Hall S, Fajardo J, Bruera E, Hui D (2014) Longitudinal temporal and probabilistic prediction of survival in a cohort of patients with advanced cancer. J Pain Symptom Manag 48(5):875–882CrossRef
26.
go back to reference Glare P, Virik K, Jones M, Hudson M, Eychmuller S, Simes J, Christakis N (2003) A systematic review of physicians' survival predictions in terminally ill cancer patients. BMJ 327(7408):195–198CrossRef Glare P, Virik K, Jones M, Hudson M, Eychmuller S, Simes J, Christakis N (2003) A systematic review of physicians' survival predictions in terminally ill cancer patients. BMJ 327(7408):195–198CrossRef
27.
go back to reference Fairchild A, Debenham B, Danielson B, Huang F, Ghosh S (2014) Comparative multidisciplinary prediction of survival in patients with advanced cancer. Support Care Cancer 22(3):611–617CrossRef Fairchild A, Debenham B, Danielson B, Huang F, Ghosh S (2014) Comparative multidisciplinary prediction of survival in patients with advanced cancer. Support Care Cancer 22(3):611–617CrossRef
28.
go back to reference Clément-Duchêne C, Carnin C, Guillemin F, Martinet Y (2010) How accurate are physicians in the prediction of patient survival in advanced lung cancer? Oncologist 15(7):782–789CrossRef Clément-Duchêne C, Carnin C, Guillemin F, Martinet Y (2010) How accurate are physicians in the prediction of patient survival in advanced lung cancer? Oncologist 15(7):782–789CrossRef
29.
go back to reference Gordon E, Daugherty C (2003) Hitting you over the head: Oncologists’ disclosure of prognosis to advanced cancer patients. Bioethics 17:142–168CrossRef Gordon E, Daugherty C (2003) Hitting you over the head: Oncologists’ disclosure of prognosis to advanced cancer patients. Bioethics 17:142–168CrossRef
Metadata
Title
Estimating survival in advanced cancer: a comparison of estimates made by oncologists and patients
Authors
M. E. S. Smith-Uffen
S. B. Johnson
A. J. Martin
M. H. N. Tattersall
M. R. Stockler
M. L. Bell
K. Detering
J. M. Clayton
W. Silvester
S. Clarke
L. Vaccaro
P. Beale
B. E. Kiely
Publication date
01-07-2020
Publisher
Springer Berlin Heidelberg
Keyword
Care
Published in
Supportive Care in Cancer / Issue 7/2020
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-019-05158-5

Other articles of this Issue 7/2020

Supportive Care in Cancer 7/2020 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine